NUS on NYSE

Nu Skin Enterprises

Logo: nuskin.com5

American multi-level marketing company

Nu Skin Enterprises, Inc. is an American multilevel marketing company that develops and sells personal care products and dietary and nutritional supplements. Under the Nu Skin and Pharmanex brands, the company sells its products in 54 markets through a network of approximately 1.2 million independent distributors. The company was founded in 1984 by Blake Roney, Nedra Roney, Sandie Tillotson, and Steven J. Lund.3 Its shares trade on NYSE under the symbol NUS.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1984Founded1

Compare with Herbalife, Cosmos Health Inc. or DataMeds AI, Inc., or pick any stock.

  • TickerNUS on NYSE1
  • Industrypersonal care product1
  • HeadquartersProvo1
  • Websitewww.nuskin.com
  • Legal formDelaware corporation1
  • Incorporated inDE6
  • Business address75 West Center St, Attn: Gregory Belliston, Provo, Ut 846016
  • Filer categoryAccelerated filer6
  • LEI54930050DETB6CP71D384
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 26597814
NuskinBuildingProvo (cropped)
Photo: UtahStizzle, CC BY 3.0, via Wikimedia Commons9

Nu Skin Enterprises, Inc. is an American multilevel marketing company that develops and sells personal care products and dietary and nutritional supplements. Under the Nu Skin and Pharmanex brands, the company sells its products in 54 markets through a network of approximately 1.2 million independent distributors. The company was founded in 1984 by Blake Roney, Nedra Roney, Sandie Tillotson, and Steven J. Lund.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

69.4%Gross margin10
4.4%Operating margin10
10.8%Net margin10
-14.3%Revenue growth, 202510
19.9%Return on equity10
0.25×Debt to equity10
$46.0MFree cash flow10

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Wellness brought in 46% of the revenue Nu Skin Enterprises broke down this way in fiscal 2025.

  1. Wellness$689.1M1046%down 9% from 2024
  2. Beauty$568.1M1038%down 17% from 2024
  3. Other Product Lines$228.0M1015%down 22% from 2024
Products and services by year
Products and services202320242025
Wellness$886.1M$757.2M$689.1M
Beauty$858.6M$681.8M$568.1M
Other Product Lines$224.4M$293.1M$228.0M

Business segments

Americas brought in 19% of the revenue Nu Skin Enterprises broke down this way in fiscal 2025.

  1. Americas$283.0M1019%down 12% from 2024
  2. Southeast Asia/Pacific$209.8M1014%down 14% from 2024
  3. Manufacturing$205.8M1014%up 2% from 2024
  4. Mainland China$195.6M1013%down 17% from 2024
  5. Japan$174.4M1012%down 4% from 2024
  6. Europe and Africa$150.2M1010%down 9% from 2024
  7. South Korea$130.2M109%down 20% from 2024
  8. Hong Kong/Taiwan$117.4M108%down 10% from 2024
  9. Rhyz Other$17.8M101%down 79% from 2024
Business segments by year
Business segments202320242025
Americas$398.2M$322.5M$283.0M
Southeast Asia/Pacific$267.2M$244.8M$209.8M
Manufacturing$181.4M$201.4M$205.8M
Mainland China$298.1M$235.2M$195.6M
Japan$207.8M$181.6M$174.4M
Europe and Africa$192.4M$164.2M$150.2M
South Korea$236.1M$163.7M$130.2M
Hong Kong/Taiwan$153.6M$130.6M$117.4M
Rhyz Other$35.2M$85.2M$17.8M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue31¢$453.8M
  • Research and development1¢$10.8M
  • Other costs56¢$824.4M
  • Income tax2¢$36.0M
  • Profit11¢$160.2M

Out of $1.5B in revenue.10

Where each dollar of operating cash went, fiscal 2025

  • Capital spending43¢$34.3M
  • Dividends paid15¢$11.8M
  • Share buybacks25¢$20.0M
  • Kept or used elsewhere18¢$14.1M

Out of $80.3M of cash from operations.10

Financial statements

Revenue1112131410$1.5B in 2025−39% since 2019
0$1.0B$2.0B$3.0B2019: $2.4B$2.4B20192020: $2.6B$2.6B2020+7%2021: $2.7B$2.7B2021+4%2022: $2.2B$2.2B2022−17%2023: $2.0B$2.0B2023−12%2024: $1.7B$1.7B2024−12%2025: $1.5B$1.5B2025−14%
Gross profit1112131410$1.0B in 2025−44% since 2019
0$1.0B$2.0B$3.0B2019: $1.8B$1.8B20192020: $1.9B$1.9B2020+5%2021: $2.0B$2.0B2021+5%2022: $1.6B$1.6B2022−21%2023: $1.4B$1.4B2023−15%2024: $1.2B$1.2B2024−13%2025: $1.0B$1.0B2025−13%
Operating income1112131410$65.8M in 2025−75% since 2019
-$200.0M0$200.0M$400.0M2019: $267.4M$267.4M20192020: $257.6M$257.6M2020−4%2021: $234.0M$234.0M2021−9%2022: $110.8M$110.8M2022−53%2023: $48.3M$48.3M2023−56%2024: -$151.6M-$151.6M20242025: $65.8M$65.8M2025
Net income1112131410$160.2M in 2025−8% since 2019
-$200.0M-$100.0M0$100.0M$200.0M2019: $173.6M$173.6M20192020: $191.4M$191.4M2020+10%2021: $147.3M$147.3M2021−23%2022: $104.8M$104.8M2022−29%2023: $8.6M$8.6M2023−92%2024: -$146.6M-$146.6M20242025: $160.2M$160.2M2025

Every line of the income statement as filed: the last 3 fiscal years, latest first.10

Period ending2025-12-312024-12-312023-12-31
Revenue$1.5B$1.7B$2.0B
Cost of sales$453.8M$550.2M$611.9M
Gross profit$1.0B$1.2B$1.4B
Selling expenses$508.4M$652.0M$742.4M
General and administrative expenses$432.1M$479.0M$546.9M
Restructuring and impairment expenses$25.1M$202.4M$19.8M
Total operating expenses$965.6M$1.3B$1.3B
Operating income (loss)$65.8M-$151.6M$48.3M
Interest expense$13.9M$26.4M$25.6M
Gain on sale$176.2M$0$0
Other income (expense), net-$31.8M$2.9M$3.9M
Income (loss) before provision for income taxes$196.2M-$175.1M$26.6M
Provision (benefit) for income taxes$36.0M-$28.5M$18.0M
Net income (loss)$160.2M-$146.6M$8.6M
Basic (in dollars per share)$3.25-$2.95$0.17
Diluted (in dollars per share)$3.18-$2.95$0.17
Basic (in shares)49.3M shares49.7M shares49.7M shares
Diluted (in shares)50.3M shares49.7M shares49.9M shares

Compare Nu Skin Enterprises with another company

Corporate structure

Nu Skin Enterprises sits at the top of its group. 3 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Nu Skin Enterprises

  • CHARLES SCHWAB INVESTMENT MANAGEMENT INC Filed SCHEDULE 13G/A on Nu Skin Enterprises, latest May 14, 2026 (2 filings since Feb 12, 2026)
  • VANGUARD GROUP INC Filed SCHEDULE 13G/A on Nu Skin Enterprises, latest Mar 27, 2026 (7 filings since Feb 10, 2022)
  • BlackRock Filed SCHEDULE 13G/A on Nu Skin Enterprises, latest Apr 17, 2025 (7 filings since Jan 26, 2022)
  • Invesco Filed SC 13G/A on Nu Skin Enterprises, latest Nov 6, 2024 (2 filings since Feb 9, 2024)
  • State Street Corporation Filed SC 13G/A on Nu Skin Enterprises, latest Oct 18, 2024 (6 filings since Feb 10, 2022)
  • Wellington Management Company Filed SC 13G/A on Nu Skin Enterprises, latest Feb 8, 2024 (3 filings since Feb 4, 2022)
  • RENAISSANCE TECHNOLOGIES LLC Filed SC 13G/A on Nu Skin Enterprises, latest Feb 13, 2023 (2 filings since Feb 11, 2022)
  • Nu Skin Enterprises Provo, Utah, United States
    • PT. Nu Skin Distribution Subsidiary · Indonesia
    • PT. Nusa Selaras Subsidiary · Indonesia

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Nu Skin Enterprises reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$768.4M10 Dec 31, 2025$732.5M10 Dec 31, 2024+4.9%
Accumulated depreciation$391.2M10 Dec 31, 2025$353.0M10 Dec 31, 2024+10.8%
Property and equipment, net$377.2M10 Dec 31, 2025$379.6M10 Dec 31, 2024−0.6%
Finance-lease assets$7.7M10 Dec 31, 2025$9.5M10 Dec 31, 2024−19.4%
Operating-lease assets (leased space)$74.0M10 Dec 31, 2025$72.6M10 Dec 31, 2024+2.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$238.6M10 Dec 31, 2025$186.9M10 Dec 31, 2024+27.7%
Marketable securities, current$1.2M10 Dec 31, 2025$11.1M10 Dec 31, 2024−89.1%
Long-term investments$4.4M10 Dec 31, 2025$3.9M10 Dec 31, 2024+14.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$83.6M10 Dec 31, 2025$83.6M10 Dec 31, 20240%
Intangible assets, net (excluding goodwill)$42.6M10 Dec 31, 2025$74.3M10 Dec 31, 2024−42.6%
Finite-lived intangibles, gross$149.3M10 Dec 31, 2025$175.7M10 Dec 31, 2024−15.0%
Accumulated amortization$131.3M10 Dec 31, 2025$126.0M10 Dec 31, 2024+4.2%

Inventory

ItemLatestA year beforeChange
Inventory, total$178.6M10 Dec 31, 2025$190.2M10 Dec 31, 2024−6.1%
Raw materials$94.9M10 Dec 31, 2025$121.9M10 Dec 31, 2024−22.1%
Finished goods$83.7M10 Dec 31, 2025$68.3M10 Dec 31, 2024+22.5%

Properties, in its own words

Our principal properties consist of the following:

● · Offices—Our principal administrative offices are our corporate headquarters in Provo, Utah and our offices in Shanghai, China.

The rest of Item 2

● · Distribution Centers—We distribute our products through distribution centers and warehouses in many of our markets, with our principal facilities being in Provo, Utah and Mainland China.

● · Research and Development Centers—We operate research and development centers in Provo, Utah and Shanghai, China.

● · Manufacturing Facilities—We operate manufacturing facilities in Mainland China, and two of our Rhyz companies (Manufacturing segment) operate manufacturing facilities in Provo, Utah, Draper, Utah and West Valley City, Utah.

We own the above properties, except we lease the manufacturing facilities in Provo, Utah and West Valley City, Utah, certain of the manufacturing facilities in China, and the land for our facilities in Shanghai, China.

Item 2 of the 10-K filed Feb 13, 2026.18

The story

In 1984, Nu Skin founders Blake Roney, Nedra Roney, Sandie Tillotson, and Steven J. Lund launched a line of skincare products using only natural ingredients. The founders aimed to create skincare products and nutritional products without unnecessary fillers with the philosophy of “all of the good, none of the bad.”

The company first served the United States market and expanded operations to Canada in 1990. In 1991, the company began operations in Asia, starting in Hong Kong. In 1996, the company listed on the New York Stock Exchange.

In 1992, Nu Skin settled with five states that accused the company of deceptive advertising and overstating distributor income. In 1994, the company paid $1 million and signed a consent decree with the FTC prohibiting it from making deceptive product claims. In 1997, the company paid an additional $1.5 million to the FTC to settle allegations of unsubstantiated claims.

In 1998, Nu Skin acquired Generation Health, the parent company of the dietary supplement company Pharmanex. According to Women's Health Letter, the Pharmanex device was designed merely to help sell more supplements, since per Nu Skin's 2002 annual report, "as customers track their skin carotenoid content, we believe they will be motivated to consistently consume LifePak for longer periods of time."

In the late 1990s, Nu Skin invested in Big Planet, a multilevel marketing company selling Internet services. The New York Times wrote that Big Planet recruited people "even if they have little knowledge of the technology that they are supposed to be selling," with a Big Planet representative quoted: "I believe people who have never touched a computer before can become hugely wealthy in this business."

In 2009, Nu Skin began working with LifeGen Technologies, a genomics company based in Madison, Wisconsin. Nu Skin acquired LifeGen in December 2011. Nu Skin claims LifeGen's genetic database aided in the development of Nu Skin's products, launching the ageLOC brand.

In 2016, Nu Skin paid a $47 million class-action settlement, citing failure to disclose that its Chinese subsidiary did not register as the direct seller. Nu Skin paid $750k in fines to the United States Securities and Exchange Commission following allegations of a bribe that saw charity funds go to a Chinese politician.

In 2021, Nu Skin's subsidiary Rhyz Inc. acquired social commerce company Mavely and acquired Dallas-based skincare company BeautyBio in 2023. In 2025, the company sold the Mavely platform for five times what it paid for the company in 2021, in a $250 million transaction to Later, the Summit Partners company.

Read the full text

Products

Nu Skin was granted a patent on a device developed by Pharmanex called a "BioPhotonic Scanner", which is designed to measure the carotenoid level in skin. The company launched its ageLOC anti-aging brand in 2008.

In 2014, Nu Skin launched the Nu Skin Facial Spa which received FDA clearance for over-the-counter cosmetic use. In 2018, the company introduced the ageLOC LumiSpa, a dual-action skin care device that uses a soft silicone treatment head to gently cleanse away dirt, oil, and makeup.

Nu Skin launched ageLOC LumiSpa iO, the company's first connected device, in 2022. LumiSpa iO is a smart treatment and cleansing device for customized skin care, popularized by Venus Williams. Nu Skin launched Nu Colour “Lash + Brow” in 2023, marketed as free of prostaglandins. In 2022, Nu Skin launched a line of Nutricentials Bioadaptive Skin Care Pumps. In 2024, the company launched Nu Skin RenuSpa iO, an FDA-cleared microcurrent body device with a connected app to view live insights during treatment. RenuSpa iO is the company's first integrated beauty and wellness device. In 2024, Nu Skin launched MYND360 as a supplement and topicals product line for cognitive health.

From Wikipedia’s article on Nu Skin Enterprises, shared under CC BY-SA 4.0.7

Leadership

Who has led Nu Skin Enterprises, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (37)

Products and brands

  • personal care product

Listed on Wikidata.1

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • PT. Nu Skin Distribution Indonesia, an Indonesia corporation8
  • PT. Nusa Selaras Indonesia, an Indonesia corporation8

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • NU SKIN ENTERPRISES INCNov 2, 1998 to Sep 13, 20196
  • NU SKIN ASIA PACIFIC INCNov 6, 1996 to Aug 13, 19986
  • NU SKIN ASIA INCSep 16, 1996 to Sep 16, 19966

Timeline

  1. Aug 21, 20268-K Executive or director change71
  2. Aug 10, 20268-K Results of operations72
  3. May 29, 20268-K Executive or director change; Shareholder vote73
  4. May 8, 20268-K Executive or director change74
  5. May 7, 20268-K Results of operations75
  6. Mar 27, 20268-K Entered a material agreement; New debt or obligation76
  7. Mar 20, 20268-K Executive or director change77
  8. Mar 9, 20268-K Executive or director change78
  9. Feb 12, 20268-K Results of operations79
  10. Nov 6, 20258-K Results of operations80
  11. Aug 7, 20258-K Results of operations81
  12. May 30, 20258-K Executive or director change; Shareholder vote82
  13. Sep 1, 2021New chief executive Ryan S. Napierski becomes CEO19
  14. Jun 29, 2017New chief executive Ritch N. Wood becomes CEO20
  15. Jan 12, 2006New chief executive M. Truman Hunt becomes CEO21
  16. 1984Founded Founded1

Calendar

Coming up

  1. Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.34 a share, on Nov 6, 2025.83

When it reported results

  1. Aug 10, 2026Reported quarterly or annual results72
  2. May 7, 2026Reported quarterly or annual results75
  3. Feb 12, 2026Reported quarterly or annual results79
  4. Nov 6, 2025Reported quarterly or annual results80
  5. Aug 7, 2025Reported quarterly or annual results81
  6. May 8, 2025Reported quarterly or annual results84
  7. Feb 13, 2025Reported quarterly or annual results85
  8. Jan 13, 2025Reported quarterly or annual results86

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

371 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 48 major events, 223 insider forms, 29 large holders, 51 other. The latest 20:

  1. Sep 10, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  2. Aug 21, 20268-K EDGAR
  3. Aug 10, 202610-Q EDGAR
  4. Aug 10, 20268-K EDGAR
  5. Jun 11, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  6. Jun 3, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  7. Jun 3, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  8. Jun 3, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  9. Jun 3, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  10. Jun 3, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  11. Jun 3, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  12. Jun 3, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  13. Jun 2, 2026144 EDGAR
  14. Jun 1, 2026144 EDGAR
  15. Jun 1, 2026S-8 EDGAR
  16. May 29, 20268-K EDGAR
  17. May 21, 2026SD EDGAR
  18. May 14, 2026SCHEDULE 13G/A EDGAR
  19. May 12, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  20. May 11, 2026144 EDGAR

The 371 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

72 open-market trades by officers, directors and large owners since October 2021: 2 buys and 70 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 2, 2026Winett James MDirectorSale7,203$5.62$40.5KForm 4
Jun 1, 2026WOODBURY EDWINA DDirectorSale7,203$5.70$41.1KForm 4
May 11, 2026Nathanson LauraDirectorSale2,676$6.73$18.0KForm 4
Nov 11, 2025Hatchett Steven KeithChief Product OfficerBuy5,500$9.61$52.9KForm 4
Sep 4, 2025Nathanson LauraDirectorSale6,489$12.22$79.3KForm 4
Sep 3, 2025Clark Chayce DavidEVP, COO and CLOSale20,000$11.97$239.4KForm 4
Aug 29, 2025CAMPBELL DANIEL WDirectorSale32,437$12.11$392.7KForm 4
Jun 2, 2025WOODBURY EDWINA DDirectorSale4,532$8.44$38.2KForm 4
Jun 2, 2025Battle Emma S.DirectorSale4,532$8.44$38.2KForm 4
May 28, 2025Hatchett Steven KeithChief Product OfficerBuy6,500$7.54$49.0KForm 4
Feb 21, 2025Battle Emma S.DirectorSale1,693$7.73$13.1KForm 4
May 28, 2024LIPMAN ANDREW DDirectorSale2,000$13.33$26.7KForm 4
May 2, 2024WOODBURY EDWINA DDirectorSale1,693$12.02$20.4KForm 4
Apr 25, 2024LIPMAN ANDREW DDirectorSale2,000$12.34$24.7KForm 4
Mar 25, 2024LIPMAN ANDREW DDirectorSale2,000$12.32$24.6KForm 4
Feb 26, 2024LIPMAN ANDREW DDirectorSale2,000$12.46$24.9KForm 4
Jan 25, 2024LIPMAN ANDREW DDirectorSale2,000$18.55$37.1KForm 4
Dec 26, 2023LIPMAN ANDREW DDirectorSale2,000$19.39$38.8KForm 4
Nov 27, 2023LIPMAN ANDREW DDirectorSale2,000$17.11$34.2KForm 4
Nov 3, 2023LIPMAN ANDREW DDirectorSale15,400$17.68$272.3KForm 4

All 72 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Ryan S. NapierskiPresident and Chief Executive Officer$1.0M$6.0M94
2025Chayce D. ClarkEVP and General Counsel$584.0K$2.5M94
2025James D. ThomasFormer EVP and Chief Financial Officer$491.6K$1.7M94
2025Steven K. HatchettEVP and Chief Product Officer$431.6K$1.5M94
2025Justin S. KeiselEVP and President of Global Sales$440.6K$1.3M94
2024Ryan S. NapierskiPresident and Chief Executive Officer$1.0M$6.0M94
2024Chayce D. ClarkEVP and General Counsel$596.0K$3.5M94
2024James D. ThomasFormer EVP and Chief Financial Officer$491.8K$2.5M94
2024Steven K. HatchettEVP and Chief Product Officer$436.1K$1.6M94
2024Justin S. KeiselEVP and President of Global Sales$366.3K$973.6K94
2023Ryan S. NapierskiPresident and Chief Executive Officer$991.9K$5.8M94
2023Chayce D. ClarkEVP and General Counsel$533.8K$2.3M94
2023James D. ThomasFormer EVP and Chief Financial Officer$410.6K$1.9M94
2023Steven K. HatchettEVP and Chief Product Officer$413.4K$1.4M94

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.4,315,878$22.8M0.0%+24,615
American Century Companies Inc2,301,308$12.2M0.0%+280,106
Coppell Advisory Solutions LLC235$11.3M0.9%New
Vanguard Capital Management LLC2,049,641$10.8M0.0%−13,709
Dimensional Fund Advisors LP1,796,745$9.5M0.0%+61,563
Prescott Group Capital Management, L.L.C.1,794,608$9.5M0.8%No change
Vanguard Portfolio Management LLC1,736,856$9.2M0.0%+27,303
Renaissance Technologies LLC1,607,692$8.5M0.0%−92,804
Charles Schwab Investment Management Inc1,452,937$7.7M0.0%−690,357
CastleKnight Management LP1,389,633$7.3M0.3%+424,200
Geode Capital Management, LLC1,269,191$6.7M0.0%+81,025
Two Sigma Investments, LP1,168,634$6.2M0.0%+156,501
State Street Corp1,009,648$5.3M0.0%−24,060
Prudential Financial Inc926,287$4.9M0.0%+549,492
Morgan Stanley905,527$4.8M0.0%+75,160
Aqr Capital Management LLC789,131$4.0M0.0%−447,207
Citadel Advisors LLC654,577$3.5M0.0%+427,192
Goldman Sachs Group Inc618,642$3.3M0.0%−130,019
Bank of New York Mellon Corp542,197$2.9M0.0%+1,348
Northern Trust Corp415,019$2.2M0.0%+13,868
Allianz Asset Management GmbH392,817$2.1M0.0%+62,293
D. E. Shaw & Co., Inc.380,690$2.0M0.0%−63,396
Bridgeway Capital Management, LLC317,074$1.7M0.0%−142,858
Vanguard Fiduciary Trust Co308,316$1.6M0.0%−841
Connor, Clark & Lunn Investment Management Ltd.301,267$1.6M0.0%−64,749

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Nu Skin Enterprises is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNU SKIN ENTERPRISES, INC.2
  • CIK0001021561
  • Employer ID (EIN)87-056530918
  • Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company18
  • Incorporated inDelaware18
  • Fiscal year endsDecember 312
  • Industry code (SIC)5122 Wholesale-Drugs, Proprietaries & Druggists' Sundries2
  • SEC reviewing officeOffice of Trade & Services, Division of Corporation Finance2
  • Business address75 West Center St, Attn: Gregory Belliston, Provo, UT 846012
  • Phone801-345-10002
  • Shares outstanding48,676,634 as of Jul 31, 202616
  • Public float$390.0M as of Jun 30, 202518
  • AuditorPricewaterhouseCoopers LLP, Salt Lake City, Utah PCAOB ID 238; it also attests to the company’s internal control over financial reporting18
  • On EDGAR sinceSep 16, 19962
  • Filings2,198 in all: 4 (1,188), 8-K (278), SC 13G/A (151), 10-Q (89), 4/A (82), SC 13G (61), 3 (39), 10-K (30)2
    All 46 form types

    5 (30), DEF 14A (30), 144 (24), ARS (16), DEFA14A (15), S-8 (15), SD (13), 8-K/A (12), CORRESP (12), S-8 POS (12), S-3/A (11), UPLOAD (11), SC 13D/A (8), S-1/A (7), S-3 (7), 10-K/A (6), 424B3 (6), POS AM (6), SCHEDULE 13G/A (4), 10-Q/A (3), 3/A (3), 424B4 (3), EFFECT (3), NT 10-Q (3), RW (3), S-1 (2), S-3ASR (2), SC 13D (2), SC TO-I/A (2), 424B2 (1), 424B7 (1), 5/A (1), 8-A12B (1), DEFR14A (1), NT 10-K (1), PRE 14A (1), SC TO-I (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Feb 13, 2026
    Quarterly report (10-Q) Aug 10, 2026
    Proxy statement (DEF 14A) Apr 3, 2026
    Latest 8-K (8-K) Aug 21, 2026

Securities registered for trading

ClassSymbolExchange
Class A Common Stock, $.001 par valueNUSNew York Stock Exchange

From the cover page of the 10-K filed Feb 13, 2026 (Section 12(b) of the Exchange Act).18

Risk factors and legal proceedings

The risks Nu Skin Enterprises names in Item 1A of its 10-K filed Feb 13, 2026: 48 risks under these headings, as written.18

  • Risks Associated with Direct Selling and Our Sales Force
  • Risks Associated with Market Conditions and Competition
  • Risks Associated with Our Operations in Mainland China
  • Risks Associated with Epidemics and Other Widespread Crises
  • International Risks
  • Human Capital Risks
  • Risks Associated with Our Manufacturing and Operations
  • Product Legal and Regulatory Risks
  • Legal, Regulatory and Compliance Risks
  • Risks Associated with Taxes, Customs and Debt
  • Intellectual Property Risks
  • Data Security and Privacy Risks
The other 48 risks
  • Sustainability Risks
  • Risks Related to Our Common Stock
  • We face a number of substantial risks. Our business, financial condition or results of operations could be harmed by any of these risks. The trading price of our common stock could decline due to any of these risks, which should be considered together with the other items in this Annual Report on Form 10-K, including Item 1. Business and Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
  • Challenges to the form of our network marketing system or to our business practices have harmed and could continue to harm our business.
  • Direct selling laws and regulations vary globally, are subject to interpretation or change, and may prohibit or severely restrict direct selling and cause our revenue and profitability to decline.
  • Improper sales force actions could harm our business.
  • Social media platforms’ decisions to prohibit, block or decrease the prominence of our sales force’s content could harm our business.
  • If our business practices or policies or the actions of our sales force are found to be in violation of applicable local regulations regarding foreigners, then we could be sanctioned and/or required to change our business model, which could significantly harm our business.
  • Our sales compensation plans or other incentives could be viewed negatively by some of our sales force, could be restricted by government regulators, and could fail to achieve desired long-term results and have a negative impact on revenue.
  • Limits on the amount of sales compensation we pay could inhibit our ability to attract and retain our sales force, negatively impact our revenue and cause regulatory risks.
  • We may be held responsible for certain taxes, assessments and other requirements relating to the activities of our sales force, which could harm our financial condition and operating results.
  • Inability of products, platforms, business opportunities and other initiatives to gain or maintain sales force and market acceptance could harm our business, and trends among older and younger generations of customers contribute to this risk.
  • Difficult economic conditions could harm our business.
  • Our markets are intensely competitive, and market conditions and the strengths of competitors may harm our business.
  • Adverse publicity concerning our business, marketing plan, products or people could harm our business and reputation.
  • Product diversion may have a negative impact on our business.
  • Our operations in Mainland China are subject to significant government scrutiny, and we could be subject to fines, operational restrictions or other penalties.
  • If direct selling regulations in Mainland China are modified, interpreted or enforced in a manner that results in negative changes to our business model or the imposition of a range of potential penalties, our business could be significantly negatively impacted.
  • Our ability to expand our business in Mainland China could be negatively impacted if we are unable to obtain additional necessary national and local government approvals in Mainland China.
  • If we are not able to register products for sale in Mainland China, our business could be harmed.
  • Epidemics and other crises have negatively impacted our business and may do so in the future.
  • Our ability to conduct business in international markets may be affected by political, legal, tax and regulatory risks.
  • We are subject to financial risks as a result of our international operations, including exposure to foreign-currency fluctuations, currency controls and inflation in foreign markets, all of which could impact our financial position and results of operations.
  • Changes to tariff and import/export regulations, and trade disputes between the United States and other jurisdictions have had a negative effect on global economic conditions and could negatively affect our business, financial results and financial condition.
  • If we are unable to retain our existing sales force and recruit additional people to join our sales force, our revenue may not increase and may even decline.
  • We depend on our key personnel and Sales Leaders, and the loss of the services provided by any of our executive officers, other key employees or key Sales Leaders could harm our business and results of operations.
  • Production difficulties, quality control problems, inaccurate forecasting, shortages in ingredients, and reliance on our suppliers could harm our business.
  • The loss of or a disruption in our manufacturing, supply chain and distribution operations, or significant expenses or violations incurred by such operations, could adversely affect our business.
  • Our business could be negatively impacted if we fail to execute our product launch process or ongoing product sales due to difficulty in forecasting or increased pressure on our supply chain, information systems and management.
  • Difficulties managing our entry or growth in certain markets could cause our business and operations to be harmed.
  • System failures, capacity constraints and other information technology difficulties could harm our business.
  • Any acquired companies or future acquisitions may expose us to additional risks.
  • Regulations governing our products, including the formulation, registration, pre-approval, marketing and sale of our products, could harm our business.
  • Government regulations and private party actions relating to the marketing and advertising of our products and services may restrict, inhibit or delay our ability to sell our products and harm our business.
  • Our operations could be harmed if we or our vendors fail to comply with Good Manufacturing Practices.
  • If our current or any future device products are determined to be medical devices in a particular geographic market, or if our sales force uses these products for medical purposes or makes improper medical claims, our ability to continue to market and distribute such devices could be harmed, and we could face legal or regulatory actions.
  • We may incur product liability claims that could harm our business.
  • We may become involved in legal proceedings and other matters that could adversely affect our operations or financial results.
  • Non-compliance or alleged non-compliance with anti-corruption laws could harm our business.
  • A failure of our internal controls over financial reporting or our regulatory compliance efforts could harm our stock price and our financial and operating results or could result in fines or penalties.
  • We are subject to changes in tax and customs laws, changes in our tax rates, the adoption of new U.S. or international tax legislation or exposure to additional tax liabilities, which could have a material and adverse impact on our effective tax rate, operating results, cash flows and financial condition.
  • Government authorities may question our tax or customs positions or change their laws in a manner that could increase our effective tax rate or otherwise harm our business.
  • A decline in our business could adversely affect our financial position and liquidity, and our debt covenants could limit our ability to pursue transactions or other opportunities that could be beneficial to our business.
  • We may be subject to claims of infringement on the intellectual property rights or trade secrets of others, resulting in costly litigation.
  • If we are unable to protect our intellectual property rights or our proprietary information and know-how, our ability to compete could be negatively impacted and the value of our products could be adversely affected.
  • Failure to maintain satisfactory compliance with certain privacy and data protections laws and regulations, and the integrity of company, employee, sales force, customer or guest data, could expose us to litigation, liability, substantial negative financial consequences and harm to our reputation.
  • The unauthorized access, use, theft or destruction of our information systems or of data that is stored in our information systems or by third parties on our behalf could impact our reputation and brand and expose us to potential liability and loss of revenues.
  • The use of artificial intelligence could adversely affect our business, results of operations and reputation.
  • Our business could be negatively impacted by corporate citizenship and sustainability matters.
  • The market price of our Class A common stock is subject to significant fluctuations due to a number of factors that are beyond our control.

Legal proceedings

From time to time, we are involved in legal proceedings arising in the ordinary course of business.

The opening of Item 3, Legal Proceedings.18

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94